|
|
 |
February 14, 2008 |
Now Available:
Download the podcast of Dr. Gaylis's video presentation
CME Opportunity:
International Society of Extremity MRI in Rheumatology Conference:
Chicago, April 10, 2008
Musculoskeletal Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.
With biweekly and special edition newsletters, MSK Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
Consumer News: Learn what your patients are reading in the popular press
Depression Rarely Discussed With RA Patients
Rheumatoid arthritis patients are at an increased risk for depression, but physicians rarely discuss the issue with them...
New from PubMed: Keep up-to-date with what is on PubMed
Risedronate for Prevention of Bone Mineral Density Loss in Patients Receiving High-Dose Glucocorticoids
Risedronate improves spinal bone mineral density in patients receiving high-dose glucocorticoids...
MSK Video Report:
Adopting Imaging in RA Management and Rheumatology Practice
Dr. Norman Gaylis discusses the role of imaging in diagnosing and treating RA...
AAPM 2008: Nearly All Back Pain Improves By 5 Years
A follow-up study of low back pain finds that >90% of patients report significant improvement within 5 years...
Autoimmunity: Kidney Damage Routinely Overlooked in RA Patients; Serum Cr Not an Adequate Check
Nearly half of RA patients have compromised renal function, half of whom should have their dosage adjusted because of kidney damage...
Arthritis: 65% More Spent on Spine Problems Bought Little Relief, JAMA Study Says
Spine-related expenditures jumped 65% from 1997 to 2005, but bought little improvement in patients' health status...
BioPharm Business: Celgene Reports More Positive Phase II Data on Apremilast in Psoriasis Patients; to Expand Dosing Level, Duration; Accelerate Advancement in Psoriasis, Psoriatic Arthritis, RA
Celgene Corp announced positive clinical data from a phase II study of apremilast (CC-10004), its lead orally bioavailable, small molecule inhibitor of TNF/PDE4, in patients with moderate-to-severe plaque psoriasis...
BioPharm Business: Hollis-Eden Initiates Phase I/II Clinical Trial With Oral Anti-Inflammatory Drug Candidate Triolex in UC; RA Study Planned in 2Q/08
Hollis-Eden Pharmaceuticals, Inc announced that it has begun a phase I/II clinical trial with Triolex (HE3286), an insulin sensitizer for ulcerative colitis...